Els Van Nieuwenhuysen

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara et al. · New England Journal of Medicine · 2024 · 116 citations · Full text

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Ignace Vergote, Els Van Nieuwenhuysen, Roisin E. O’Cearbhaill et al. · Journal of Clinical Oncology · 2023 · 71 citations · Full text

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.

Domenica Lorusso, Ignace Vergote, Roisin E. O’Cearbhaill et al. · Journal of Clinical Oncology · 2022 · 21 citations

Metastatic Cervical Cancer, Tv Monotherapy, Median Duration +22

LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Annals of Oncology · 2023 · 11 citations · Full text

Medicine, Cancer Management, Gynecology +9

Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer

Charlotte Maene, Rawand Salihi, Els Van Nieuwenhuysen et al. · International Journal of Gynecological Cancer · 2021 · 10 citations